PubMed

Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.

Espinoza-Fonseca LM.

Theor Biol Med Model. 2005 Sep 20;2:38.PMID: 16174299 [PubMed - indexed for MEDLINE]Related articlesFree article

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G.

Nat Med. 2004 Dec;10(12):1321-8. Epub 2004 Nov 21.PMID: 15558054 [PubMed - indexed for MEDLINE]Related articles

HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, Soddu S.

Cancer Res. 2009 Aug 1;69(15):6241-8. Epub 2009 Jul 28.PMID: 19638586 [PubMed - indexed for MEDLINE]Related articles

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.

Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D, Bernard D, Bradford CR, Carey TE, Wang S.

Mol Cancer Ther. 2008 Jun;7(6):1533-42.PMID: 18566224 [PubMed - indexed for MEDLINE]Related articlesFree article

Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M.

Curr Cancer Drug Targets. 2005 Feb;5(1):57-68. Review.PMID: 15720190 [PubMed - indexed for MEDLINE]Related articles

Small molecules targeting p53 to improve antitumor therapy.

Beretta GL, Gatti L, Benedetti V, Perego P, Zunino F.

Mini Rev Med Chem. 2008 Aug;8(9):856-68. Review.PMID: 18691143 [PubMed - indexed for MEDLINE]Related articles

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.

Di Cintio A, Di Gennaro E, Budillon A.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):1-13.PMID: 19663772 [PubMed - indexed for MEDLINE]Related articles

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, Lin J.

Br J Cancer. 2009 Sep 1;101(5):774-81.PMID: 19707204 [PubMed - indexed for MEDLINE]Related articles

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Shangary S, Wang S.

Annu Rev Pharmacol Toxicol. 2009;49:223-41. Review.PMID: 18834305 [PubMed - indexed for MEDLINE]Related articlesFree article

A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy.

Sun SH, Zheng M, Ding K, Wang S, Sun Y.

Cancer Biol Ther. 2008 Jun;7(6):845-52. Epub 2008 Mar 5.PMID: 18340116 [PubMed - indexed for MEDLINE]Related articles

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.

Cheok CF, Dey A, Lane DP.

Mol Cancer Res. 2007 Nov;5(11):1133-45.PMID: 18025259 [PubMed - indexed for MEDLINE]Related articlesFree article

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, Roller PP, Wang S.

J Med Chem. 2006 Jun 15;49(12):3432-5.PMID: 16759082 [PubMed - indexed for MEDLINE]Related articles

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.

Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8. Epub 2008 Mar 3.PMID: 18316739 [PubMed - indexed for MEDLINE]Related articlesFree article

Small molecule inhibitors of the p53-MDM2.

Hu CQ, Hu YZ.

Curr Med Chem. 2008;15(17):1720-30. Review.PMID: 18673221 [PubMed - indexed for MEDLINE]Related articles

p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.

Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES, Selivanova G.

Cell Cycle. 2009 Nov 1;8(21):3576-83. Epub 2009 Nov 1.PMID: 19838062 [PubMed - indexed for MEDLINE]Related articles

Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.

Lu Y, Nikolovska-Coleska Z, Fang X, Gao W, Shangary S, Qiu S, Qin D, Wang S.

J Med Chem. 2006 Jun 29;49(13):3759-62.PMID: 16789731 [PubMed - indexed for MEDLINE]Related articles

Targeting the p53-MDM2 interaction to treat cancer.

Klein C, Vassilev LT.

Br J Cancer. 2004 Oct 18;91(8):1415-9. Review.PMID: 15452548 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeting the MDM2-p53 interaction for cancer therapy.

Shangary S, Wang S.

Clin Cancer Res. 2008 Sep 1;14(17):5318-24. Review.PMID: 18765522 [PubMed - indexed for MEDLINE]Related articlesFree article

Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.

Chène P.

Mol Cancer Res. 2004 Jan;2(1):20-8. Review.PMID: 14757842 [PubMed - indexed for MEDLINE]Related articlesFree article

Recent advances in validating MDM2 as a cancer target.

Rayburn ER, Ezell SJ, Zhang R.

Anticancer Agents Med Chem. 2009 Oct;9(8):882-903. Review.PMID: 19538162 [PubMed - indexed for MEDLINE]Related articles